SS-31 Peptide: The Complete Research Guide (Elamipretide)
SS-31, formally known as Elamipretide, is one of the few research peptides that doesn’t work through a receptor at all. While most peptides bind a cell-surface receptor and trigger a signaling cascade several steps removed from their actual chemistry, SS-31 crosses directly into the mitochondria and physically binds a specific membrane lipid. That distinction is the reason it keeps showing up across such a wide range of research — from heart failure models to neurodegeneration studies to basic aging biology.
This guide covers where SS-31 came from, how it actually works, what the published research says about it, and how it fits alongside the other mitochondrial and longevity peptides researchers study it with.
For laboratory research use only. This article is for educational purposes and does not constitute medical advice.
Where SS-31 Came From
SS-31 stands for Szeto-Schiller peptide 31, named after its developers, Dr. Hazel Szeto and Dr. Peter Schiller, who created it as part of a research program at Cornell University studying mitochondria-targeted compounds. It’s also known by the pharmaceutical name Elamipretide, along with the development codes Bendavia and MTP-131, used across different stages of its clinical research history.
The compound is a synthetic tetrapeptide with the sequence D-Arg-2′,6′-Dmt-Lys-Phe-NH2. That specific sequence isn’t arbitrary — it alternates aromatic and positively charged (cationic) residues, a pattern engineered because it shows strong affinity for cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane.
How SS-31 Actually Works
Most mitochondria-targeted compounds simply accumulate inside the mitochondria and scavenge free radicals wherever they happen to be. SS-31 does something more specific: it binds directly to cardiolipin on the inner membrane, where the electron transport chain does the actual work of producing cellular energy.
This matters because cardiolipin isn’t just structural. It’s required for properly assembling the electron transport chain complexes, particularly Complex I and Complex IV, and it helps regulate the mitochondrial permeability transition pore (mPTP) — a channel that, when it opens uncontrollably under oxidative stress, triggers the cell’s self-destruction pathway.
A 2023 study from the University of Washington, published in GeroScience, found that SS-31 improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT), a transport protein SS-31 binds directly. In practical terms, this means aged mitochondria treated with SS-31 became more responsive to the signals that trigger ATP production, addressing a specific bottleneck that worsens with age. Separately, live-cell imaging research examining apoptosis found that SS-31 slowed the recruitment of BAX, a protein that initiates programmed cell death, and accelerated the formation of larger, healthier mitochondria under stress conditions.
Beyond Cardiolipin: What Else the Research Shows
While cardiolipin stabilization is SS-31’s signature mechanism, the published research base extends further than that single interaction.
A 2019 mouse study examining lipopolysaccharide-induced cognitive impairment found that Elamipretide reduced mitochondrial reactive oxygen species, helped maintain mitochondrial membrane potential, and was associated with measurable improvements in memory and synaptic function in the treated animals. Researchers have also studied SS-31 in models of ischemia-reperfusion injury, where restoring mitochondrial function quickly after blood flow is restored is a critical factor in how much tissue damage occurs, along with kidney-specific ischemia models where similar mitochondrial protection has been documented.
The Clinical Trial History
Unlike most research peptides, SS-31 has an unusually developed clinical trial record. Stealth BioTherapeutics has run Phase II and Phase III trials examining Elamipretide in Barth syndrome, primary mitochondrial myopathy, and heart failure, and the compound holds an FDA Rare Pediatric Disease designation. It’s also been studied in an investigator-initiated trial for Friedreich’s Ataxia (FRDA), a genetic condition involving progressive mitochondrial dysfunction that shares overlapping biology with Barth syndrome.
The clearest outcome of that clinical history is the FDA’s approval of Elamipretide for Barth syndrome, a rare genetic disorder caused by mutations affecting cardiolipin remodeling. That approval doesn’t extend to research-grade SS-31 sold for laboratory use, but it does confirm, in a real human disease context, that the cardiolipin-targeting mechanism this compound was designed around actually holds up under clinical scrutiny.
Research Applications
Across the published literature, SS-31 shows up most often in a few recurring research contexts: cardiac and skeletal muscle mitochondrial dysfunction models, aging biology studies examining whether restoring inner-membrane function reverses age-related mitochondrial decline, neurodegenerative disease research including Parkinson’s models, and ischemia-reperfusion injury models across multiple organ systems. Because SS-31 binds cardiolipin specifically, it also functions as a molecular probe for studying cardiolipin’s broader role in respiratory chain assembly and cytochrome c retention.
How SS-31 Fits Among Mitochondrial and Longevity Research Peptides
SS-31 rarely gets studied in isolation — it’s usually discussed alongside a small group of other peptides that approach cellular aging and mitochondrial biology from different angles.
MOTS-C is the peptide SS-31 is most frequently compared to, and the two are easy to confuse as interchangeable. They aren’t. SS-31 works through direct physical binding to cardiolipin — a membrane chemistry intervention. MOTS-C, by contrast, is a peptide encoded within mitochondrial DNA that works by activating AMPK, a cellular energy-sensing pathway, functioning more like a systemic metabolic hormone than a membrane-level intervention. Explore our MOTS-C research peptide for the full mechanism breakdown.
Humanin shares SS-31’s mitochondrial origin story in one sense — it’s also a mitochondrial-derived peptide — but its research focus is almost entirely different, centered on cytoprotection and resistance to programmed cell death through IGFBP3 and Bax interactions, rather than membrane chemistry. Our Humanin research guide covers this in detail.
Epithalon approaches longevity from an entirely separate angle again — telomerase activation and telomere maintenance, rather than mitochondrial function directly. Researchers studying broad longevity biology often examine SS-31 and Epithalon side by side precisely because they intervene on two of the most-cited mechanisms of cellular aging: mitochondrial decline and telomere shortening.
Purity and Research Reliability
Given how much of SS-31’s documented research depends on precise, reproducible mitochondrial measurements, purity is not a minor detail. Every batch of Patriot Peptides SS-31 (5mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity, endotoxin, and sterility, with a batch-specific Certificate of Analysis available for every order.
Frequently Asked Questions
What is SS-31 peptide?
SS-31 (Elamipretide) is a synthetic tetrapeptide that binds directly to cardiolipin on the inner mitochondrial membrane, stabilizing mitochondrial structure and function. It’s FDA-approved under the name Elamipretide for Barth syndrome, a rare cardiolipin-related genetic disorder.
What are the benefits of SS-31 in research studies?
Published research has documented several findings in animal and cellular models: reduced mitochondrial reactive oxygen species production, improved ADP sensitivity in aged mitochondria, slowed BAX-mediated apoptosis, and improvements in memory and synaptic function in cognitive impairment models. All findings come from laboratory and preclinical research.
Is SS-31 FDA approved?
SS-31, under the pharmaceutical name Elamipretide, is FDA-approved for Barth syndrome and holds an FDA Rare Pediatric Disease designation. Research-grade SS-31 sold for laboratory use is a separate product from the approved pharmaceutical and is not intended for human use.
What is the difference between SS-31 and MOTS-C?
SS-31 works through direct physical binding to cardiolipin on the inner mitochondrial membrane. MOTS-C is a mitochondrial DNA-encoded peptide that activates the AMPK pathway, functioning as a systemic metabolic signal rather than a membrane-level intervention.
Are there side effects associated with SS-31 in research?
In clinical trials of Elamipretide, injection site reactions were the most commonly reported effect, with the compound generally described as well-tolerated across Phase II and III studies. Research-grade SS-31 for laboratory use has not undergone the same safety evaluation and is not intended for human administration.
What happened to Peptide Sciences’ SS-31?
Peptide Sciences shut down in March 2026. Patriot Peptides SS-31 (5mg) is available now, manufactured in cGMP-certified US facilities with independent third-party testing on every batch.
Where can I buy research-grade SS-31?
Patriot Peptides SS-31 (5mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity, endotoxin, and sterility, with a batch-specific Certificate of Analysis for every order.